Levetiracetam 1a Farma (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates the release of neurotransmitters. This action stabilizes neuronal firing and diminishes hyperexcitability in the brain, thereby lowering the likelihood of seizure initiation and spread.

The dosage of levetiracetam is individualized and determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Patients should follow the dose prescribed by their healthcare professional and not adjust it without medical advice.

Levetiracetam is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy if the potential benefit justifies the risk. Small amounts are excreted in breast milk; breastfeeding decisions should be made with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Levetiracetam offers a favorable safety profile and minimal drug‑enzyme interactions compared with many older antiepileptics such as carbamazepine or phenytoin. Its rapid absorption and lack of significant hepatic metabolism make it a convenient option, though individual response and tolerability vary among patients.

Store the tablets at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Do not refrigerate or freeze the product, and keep it out of reach of children.

Levetiracetam 1a Farma is taken orally, usually with or without food, as a tablet. The exact administration schedule—once daily, twice daily, or more—depends on the prescriber’s instructions and the patient’s therapeutic needs.

Serious risks include severe skin reactions (e.g., Stevens‑Johnson syndrome), suicidal thoughts or behavior, significant mood changes such as depression, and rare blood disorders. Patients should seek immediate medical attention if they notice rash, mood alterations, or signs of infection.

Levetiracetam is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with severe renal impairment, as dose adjustment may be required, and for those with a history of psychiatric disorders.